Claudio Faria

415 total citations
32 papers, 329 citations indexed

About

Claudio Faria is a scholar working on Oncology, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Claudio Faria has authored 32 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 9 papers in Cancer Research and 7 papers in Economics and Econometrics. Recurrent topics in Claudio Faria's work include Cancer Treatment and Pharmacology (11 papers), Economic and Financial Impacts of Cancer (6 papers) and Breast Cancer Treatment Studies (6 papers). Claudio Faria is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Economic and Financial Impacts of Cancer (6 papers) and Breast Cancer Treatment Studies (6 papers). Claudio Faria collaborates with scholars based in United States, Japan and United Kingdom. Claudio Faria's co-authors include Ronda Copher, Marco DiBonaventura, Siyeon Park, Monika Parisi, Quanhong Ni, Fadi Braiteh, Karen W. Lee, Xīn Gào, Daniel Belletti and Lee S. Schwartzberg and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Claudio Faria

29 papers receiving 321 citations

Peers

Claudio Faria

ONCOL

PRM

EPIDE

Chenjie Zeng United States

Mingjun Rui China

Sharon Peacock Hinton United States

Patrick Peterson United States

Rajeshwari Punekar United States

Per-Olof Thuresson Switzerland

Saskia de Groot Netherlands

Brielan Smiechowski Canada

Meaghan Krohe United States

Yat Ming Lau China

Chenjie Zeng United States

Claudio Faria

156 ×1.0

ONCOL

87 ×1.2

PRM

44 ×0.6

39 ×0.7

32 ×0.9

EPIDE

Citations per year, relative to Claudio Faria Claudio Faria (= 1×) peers Chenjie Zeng

Countries citing papers authored by Claudio Faria

Since Specialization

Citations

This map shows the geographic impact of Claudio Faria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudio Faria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudio Faria more than expected).

Fields of papers citing papers by Claudio Faria

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudio Faria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudio Faria. The network helps show where Claudio Faria may publish in the future.

Co-authorship network of co-authors of Claudio Faria

This figure shows the co-authorship network connecting the top 25 collaborators of Claudio Faria. A scholar is included among the top collaborators of Claudio Faria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudio Faria. Claudio Faria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faria, Claudio, et al.. (2025). O USO DAS REDES SOCIAIS E A ASCENSÃO DE TRANSTORNOS MENTAIS NOS ADOLESCENTES: UMA REVISÃO DE LITERATURA.. Revista fisio&terapia.. 29(143). 24–25.

Popoff, Evan, et al.. (2020). PRO36 A US COST-MINIMIZATION MODEL COMPARING LIFETIME PER-PATIENT COSTS FOR RAVULIZUMAB AND ECULIZUMAB FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME. Value in Health. 23. S335–S335. 1 indexed citations

Parisi, Monika, Stefan Glück, Sungha Park, et al.. (2018). Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. SHILAP Revista de lepidopterología. 2 indexed citations

Mahtani, Reshma, Monika Parisi, Stefan Glück, et al.. (2018). Comparative effectiveness of early-line <em>nab</em>-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis. Cancer Management and Research. Volume 10. 249–256. 23 indexed citations

Feldman, Tatyana, Charles M. Farber, Claudio Faria, et al.. (2017). Treatment of Peripheral T-Cell Lymphoma in Community Settings. Clinical Lymphoma Myeloma & Leukemia. 17(6). 354–361. 4 indexed citations

Braiteh, Fadi, Manish Patel, Monika Parisi, et al.. (2017). Comparative effectiveness and resource utilization of <em>nab</em>-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Management and Research. Volume 9. 141–148. 31 indexed citations

Weiss, Jared, et al.. (2016). Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non–Small-cell Lung Cancer in a US Community Oncology Setting. Clinical Lung Cancer. 18(4). 372–380.e1. 3 indexed citations

Braiteh, Fadi S., et al.. (2016). Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting.. Journal of Clinical Oncology. 34(4_suppl). 433–433.

Braiteh, Fadi S., et al.. (2016). Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus gemcitabine monotherapy (G) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting.. Journal of Clinical Oncology. 34(4_suppl). 429–429.

10.

Tremblay, Gabriel, et al.. (2014). Economic Burden of Chemotherapy Related Toxicities in Third Line Metastatic Breast Cancer Patients. Value in Health. 17(7). A628–A628. 2 indexed citations

11.

DiBonaventura, Marco, et al.. (2014). The Association Between Non-Adherence and Quality of Life Among Women with Metastatic Breast Cancer. Value in Health. 17(3). A92–A92. 1 indexed citations

12.

DiBonaventura, Marco, et al.. (2014). Patient Preferences Of Treatments Among Women With Metastatic Breast Cancer: Results From A Conjoint Analysis Study. Value in Health. 17(3). A4–A4. 1 indexed citations

13.

Dranitsaris, George, Stefan Glück, Claudio Faria, David L. Cox, & Hope S. Rugo. (2014). Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting. Clinical Therapeutics. 37(1). 134–144. 13 indexed citations

14.

Broder, Michael S., et al.. (2014). The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.. PubMed. 7(3). 171–82. 11 indexed citations

15.

Wan, Yin, et al.. (2013). Indirect costs associated with metastatic breast cancer. Journal of Medical Economics. 16(10). 1169–1178. 42 indexed citations

16.

Schilling, Brian J., et al.. (2011). PCV32 BUDGET IMPACT ANALYSIS OF INCREASING LMWH/FXI UTILIZATION. Value in Health. 14(3). A38–A38. 1 indexed citations

17.

Rugo, H. S., et al.. (2011). P1-08-07: Survival in US Women Following an Indication of Metastatic Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-Medicare Analysis.. Cancer Research. 71(24_Supplement). P1–8. 3 indexed citations

18.

Longui, Carlos Alberto, et al.. (2010). Applicability of Real-Time PCR Methodology in the Neonatal Detection of Turner Syndrome. Hormone and Metabolic Research. 42(9). 677–681. 6 indexed citations

19.

Faria, Claudio, et al.. (2009). A narrative review of clinical inertia: focus on hypertension. Journal of the American Society of Hypertension. 3(4). 267–276. 42 indexed citations

20.

Silva, Tatiane Sousa e, et al.. (2008). Impact of Prolonged Physical Training on the Pituitary Glucocorticoid Sensitivity Determined by Very Low Dose Intravenous Dexamethasone Suppression Test. Hormone and Metabolic Research. 40(10). 718–721. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact